[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-364567-105":59,"doc-detail-364567-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","t-cell-immune-checkpoint-inhibition-plus-hypomethylation-for-locally-advanced-her2-negative-breast-cancer-a-phase-2-neoadjuvant-window-trial-of-decitabine-and-pembrolizumab-followed-by-standard-neoadjuvant-chemotherapy","T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy","","Phase 2 neoadjuvant window trial evaluates whether DNA methyltransferase inhibition plus immune checkpoint blockade increases stromal TILs before standard neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer. Patients received decitabine followed by pembrolizumab in a window prior to starting NCT; biopsies before and after window therapy assessed TILs and PD-L1. Forty-six patients were treated with multi-cohort analyses showing DNMTi plus ICB depleted MDSCs, increased stromal lymphocyte infiltration, and raised PD-L1 expression with manageable safety.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/t-cell-immune-checkpoint-inhibition-plus-hypomethylation-for-locally-advanced-her2-negative-breast-cancer-a-phase-2-neoadjuvant-window-trial-of-decitabine-and-pembrolizumab-followed-by-standard-neoadjuvant-chemotherapy/364567/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/t-cell-immune-checkpoint-inhibition-plus-hypomethylation-for-locally-advanced-her2-negative-breast-cancer-a-phase-2-neoadjuvant-window-trial-of-decitabine-and-pembrolizumab-followed-by-standard-neoadjuvant-chemotherapy/364567.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What primary objective did the phase 2 window trial test?","Question",{"text":112,"@type":113},"To determine whether DNA methyltransferase inhibitors combined with immune checkpoint blockade would increase stromal TILs in primary breast cancers before neoadjuvant chemotherapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients treated before standard neoadjuvant chemotherapy?",{"text":117,"@type":113},"Patients received window immunotherapy with decitabine followed by pembrolizumab, then proceeded to standard neoadjuvant chemotherapy and tumor resection.",{"name":119,"@type":110,"acceptedAnswer":120},"What immune biomarkers changed after the window treatment?",{"text":121,"@type":113},"The study reports depletion of systemic monocytic MDSCs, increased stromal lymphocyte infiltration, and increased PD-L1 expression in primary breast cancers.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},364567,1790203735,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Open access Original research  \n T-cell immune checkpoint inhibition plus  \nhypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy  \nHarry D Bear  ,1 Xiaoyan Deng,1 Dipankar Bandyopadhyay,1 Michael Idowu,1 Taylor M Jenkins,1 Maciej Kmieciak,1 Monique Williams,1 Giovanni Archer,1 Lindsey Gwaltney,1 Patrick Dillon,2 Daniel Flora,3 Daniel Stover  ,4  \nAndrew S Poklepovic,1 Mary Hackney,1 Masey Ross,1 Hetal Vachhani,1 Raphael Louie,1 Kandace P McGuire,1 Amelia Grover,1 Tasnim Rahman,5 Amber Hendrix1  \nTo cite: Bear HD, Deng X, Bandyopadhyay D, et al. T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy. Journal for ImmunoTherapy of Cancer 2025;13:e010294 . doi:10 . 1136/ jitc-2024-010294  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2024-010294](jitc-2024-010294)) .  \nAccepted 12 February 2025  \n© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Harry D Bear; [hdbear@vcu.edu](hdbear@vcu.edu)  \nABSTRACT  \nBackground Higher levels of tumor-infiltrating lymphocytes (TILs) in breast cancers are associated with increased likelihood of pathologic complete response (pCR) to chemotherapy. DNA methyltransferase inhibitors (DNMTi) can augment immune responses to cancers, decreasing myeloid-derived suppressor cells (MDSCs) and increasing T lymphocyte responsiveness. We have shown that the DNMTi decitabine augments the effectiveness of immunotherapy using murine triple-negative breast cancer (TNBC) models. The primary objective was to determine whether DNMTi+immune checkpoint blockade would increase stromal TIL (sTIL) in primary breast cancers before neoadjuvant chemotherapy (NCT) .  \nMethods In a phase 2 study (NCT02957968), patients with human epidermal growth factor receptor 2-negative breast cancer received window immunotherapy—decitabine (15 mg/m2×4 doses over 5 days) followed by 2 doses of pembrolizumab (200 mg, 2 weeks apart)—before starting NCT. Biopsies before and after window immunotherapy quantified TILs and programmed death-ligand 1 (PD-L1) expression. Patients proceeded to NCT and tumor resection per standard of care. Mid-study, results of the KEYNOTE 522 trial led to patients with TNBC receiving additional pembrolizumab concurrently with standard NCT and in the adjuvant setting.  \nResults 46 patients (median age 54.5 years, range 28–72; 71.7% white, 28.3% black; 100% female) were treated. 21 patients had TNBC and received neither neoadjuvant pembrolizumab concurrently with NCT noradjuvant pembrolizumab (Cohort A), 7 patients had TNBC and did receive concurrent and/or adjuvant pembrolizumab (Cohort A2), and 18 patients were estrogen receptor positive and/or progesterone receptor positive and received neither concurrent nor adjuvant pembrolizumab (Cohort B) . Blood samples collected after decitabine  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ Evidence of immune responsiveness in breast cancer tumor microenvironments (TME) predict for better prognosis and higher likelihood of response toneoadjuvant chemotherapy (NCT), but little had been done to modify the TME prior to initiation of NCT. Moreover, myeloid-derived suppressor cells (MDSC), which can be depleted by treatment with DNA methyltransferase inhibitors (DNMTi), are known to suppress immune responses in murine cancer models and are associated with poor prognosis in women with breast cancer. Finally, gene methylation in T lymphocytes contributes to T cell exhaustion and resistance","cbCaiiAbAG17HsDc","https://ap.wps.com/l/cbCaiiAbAG17HsDc","pdf",1098461,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Neoadjuvant chemotherapy rationale","[{\"question\":\"What primary objective did the phase 2 window trial test?\",\"answer\":\"To determine whether DNA methyltransferase inhibitors combined with immune checkpoint blockade would increase stromal TILs in primary breast cancers before neoadjuvant chemotherapy.\"},{\"question\":\"How were patients treated before standard neoadjuvant chemotherapy?\",\"answer\":\"Patients received window immunotherapy with decitabine followed by pembrolizumab, then proceeded to standard neoadjuvant chemotherapy and tumor resection.\"},{\"question\":\"What immune biomarkers changed after the window treatment?\",\"answer\":\"The study reports depletion of systemic monocytic MDSCs, increased stromal lymphocyte infiltration, and increased PD-L1 expression in primary breast cancers.\"}]","T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy | PDF",1790158233,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ebf9ff78a781fb90bc9dffe0fba2669c.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e0b66ea3c5f399d3bb8efff7e7858ac.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/10367ea40110ce57b96bf24300f109ea.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/be20ddb6995f31e032fd23be91e7f097.webp",980,1306]